P A Gurbel

Summary

Affiliation: Sinai Hospital of Baltimore
Country: USA

Publications

  1. Tantry U, Gesheff M, Liu F, Bliden K, Gurbel P. Resistance to antiplatelet drugs: what progress has been made?. Expert Opin Pharmacother. 2014;15:2553-64 pubmed publisher
    ..The therapeutic window concept for the P2Y12 receptor blocker therapy may facilitate the balance between reducing ischemic events and avoiding bleeding events, thereby improving net clinical outcome. ..
  2. Chaudhary R, Bliden K, Tantry U, Mohammed N, Mathew D, Gesheff M, et al. Association of weight gain with coronary artery disease, inflammation and thrombogenicity. J Thromb Thrombolysis. 2016;41:394-403 pubmed publisher
    ..05). Our data suggest that maximal weight gain since age 17 years is associated with heightened thrombogenicity, inflammation and a poorer lipid profile but not an increased risk for severe CAD development. ..
  3. Gurbel P, Bliden K, Cohen E, Navickas I, Singla A, Antonino M, et al. Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. Blood Coagul Fibrinolysis. 2008;19:268-75 pubmed publisher
    ..Point-of-service measurements of platelet-fibrin clot characteristics may lead to more intensified antithrombotic therapy and reduced mortality in selected patients. ..
  4. Gurbel P, Bliden K, Saucedo J, Suarez T, DiChiara J, Antonino M, et al. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatid. J Am Coll Cardiol. 2009;53:648-57 pubmed publisher
    ..Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin [CLEAR PLATELETS-2]; NCT00370045. ..
  5. Liu F, Tantry U, Gurbel P. P2Y12 receptor inhibitors for secondary prevention of ischemic stroke. Expert Opin Pharmacother. 2015;16:1149-65 pubmed publisher
    ..Short-term (≤ 3 months) dual antiplatelet therapy with clopidogrel and aspirin that is initiated early after IS or transient ischemic attack due to large artery atherosclerosis appears most efficient. ..
  6. Franzese C, Bliden K, Gesheff M, Pandya S, Guyer K, Singla A, et al. Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy. Am J Cardiol. 2015;115:1204-11 pubmed publisher
    ..Future prospective studies to compare FOS with lipid-lowering therapy and to assess the independent effects of FOS on thrombogenicity are needed. ..
  7. request reprint
    Gurbel P, Bliden K, Guyer K, Aggarwal N, Tantry U. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thromb Res. 2007;119:563-70 pubmed
    ..Measurement of R may serve as a new indicator of clopidogrel responsiveness. ..
  8. request reprint
    Gurbel P, Bliden K, DiChiara J, Newcomer J, Weng W, Neerchal N, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007;115:3156-64 pubmed
    ..The observation of dose-dependent effects despite nearly complete inhibition of AA-induced aggregation suggests that aspirin may exert antiplatelet properties through non-cyclooxygenase-1 pathways and deserves further investigation. ..
  9. Gurbel P, Shuldiner A, Bliden K, Ryan K, Pakyz R, Tantry U. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am Heart J. 2011;161:598-604 pubmed publisher
    ..Because both predict cardiovascular events with similar risk ratios, CYP2C19 genotyping and HPR may provide complementary information to stratify risk and personalized DAPT in stented patients than either alone. ..

More Information

Publications19

  1. Gurbel P, Kuliopulos A, Tantry U. G-protein-coupled receptors signaling pathways in new antiplatelet drug development. Arterioscler Thromb Vasc Biol. 2015;35:500-12 pubmed publisher
    ..Greater understanding of the mechanisms of G-protein-coupled receptor-mediated signaling may allow the tailoring of antiplatelet therapy. ..
  2. Gurbel P, Bliden K, Fort J, Jeong Y, SHULDINER A, Chai S, et al. Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. Am Heart J. 2013;165:176-82 pubmed publisher
    ..These finding are directly relevant to the treatment for patients with high gastrointestinal risk who require dual-antiplatelet therapy and gastroprotection. ..
  3. Gurbel P, Bliden K, Logan D, Kereiakes D, Lasseter K, White A, et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol. 2013;62:505-12 pubmed publisher
    ..The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease; NCT01260584). ..
  4. Gurbel P, Tantry U. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation. 2012;125:1276-87; discussion 1287 pubmed publisher
  5. Gurbel P, Bliden K, Butler K, Tantry U, Gesheff T, Wei C, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577-85 pubmed publisher
    ..Ticagrelor achieved more rapid and greater platelet inhibition than high-loading-dose clopidogrel; this was sustained during the maintenance phase and was faster in offset after drug discontinuation. ..
  6. Tantry U, Navarese E, Gurbel P. Does Gender have an Influence on Platelet Function and the Efficacy of Oral Antiplatelet Therapy?. Interv Cardiol Clin. 2012;1:223-230 pubmed publisher
    ..In vitro studies support the attenuation of platelet function by estrogen. Sufficient data support the presence of gender differences in thrombogenicity to promote further investigation in this area. ..
  7. Gurbel P, Tantry U. The Role of Platelet Function Testing in Risk Stratification and Clinical Decision-Making. Interv Cardiol Clin. 2013;2:607-614 pubmed publisher
    ..At this time, it seems most reasonable to assess platelet function in high-risk clopidogrel-treated patients. ..
  8. request reprint
    Gurbel P, Kreutz R, Bliden K, DiChiara J, Tantry U. Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. Am Heart J. 2008;155:56-61 pubmed
    ..The early implementation of a biomarker analysis may identify the patient at risk for plaque progression and refine the definition of "stable" angina. ..
  9. Tantry U, Bonello L, Aradi D, Price M, Jeong Y, Angiolillo D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261-73 pubmed publisher
    ..In addition, we propose cutoff values for high and low on-treatment platelet reactivity to ADP that might be used in future investigations of personalized antiplatelet therapy. ..
  10. Gurbel P, Bliden K, Antonino M, Stephens G, Gretler D, Jurek M, et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J Thromb Haemost. 2010;8:43-53 pubmed publisher
    ..16%, P = 0.0004). HPR is reversibly overcome by a single 60-mg oral dose of elinogrel, a drug now being investigated in a phase 2 trial. CYP2C19*2 was associated with HPR during conventional dual antiplatelet therapy. ..